Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3368696 | 0.93 | PGR (0.47) | PGRHRH3 | |
| SCHEMBL3362441 | 0.89 | HRH3 (0.64) | HRH3 | |
| SCHEMBL3368320 | 0.89 | L3MBTL1 (0.47) | HRH3L3MBTL1 | |
| SCHEMBL3365272 | 0.89 | FFAR1 (0.51) | HRH3L3MBTL1 | |
| SCHEMBL3368422 | 0.88 | HRH3 (0.53) | PGRHRH3 | |
| SCHEMBL3365222 | 0.88 | HRH3 (0.66) | HRH3 | |
| SCHEMBL3367135 | 0.88 | HRH3 (0.66) | HRH3 | |
| SCHEMBL3365072 | 0.86 | HRH3 (0.55) | HRH3 | |
| SCHEMBL3364865 | 0.86 | HRH3 (0.46) | HRH3L3MBTL1 | |
| SCHEMBL3369182 | 0.86 | HRH3 (0.51) | PGRHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303503-B1 | ANILINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-6683201-B2 | FOR THERAPY AND PROPHYLAXIS OF HYPERCHOLESTEROLEMIA, HYPERLIPEMIA, ARTERIOSCLEROSIS, VASCULAR DISEASES, MYCOSES, PARASITE INFECTIONS, GALLSTONES, TUMORS AND/OR HYPERPROLIFERATIVE DISORDERS, DIABETES | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| EP-1303503-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-03-28 | — | — | US | disclosed |
| WO-2002006189-A2 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | LSS, CYP51A1, CYP46A1 | PGR 2421/4885HRH3 3372/4885L3MBTL1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.